Using western blotting, we found that after treatment with the same concentration of sorafenib, the levels of xCT and GPX4 were increased, whereas the levels of DMT1 were decreased in drug-resistant HCC cells or FNDC5-overexpressing HCC cells compared with those in sorafenib-sensitive HCC cells. This evidence concerns the gene GPX4 and hepatocellular carcinoma.